Background Standard treatment of cutaneous leishmaniasis (CL) in Suriname entails three injections of pentamidine isethionate (PI) 4 mg/kg per injection in 7 days (7 day regimen). Compliance to treatment is low and may contribute to increasing therapy failure. A 3 day regimen, including 2 injections of 7 mg/kg in 3 days may increase compliance. Methods In a randomized, single-blinded non-inferiority trial conducted in Suriname, 84 CL patients received the 7 day regimen and 79 CL patients received the 3 day regimen. Primary objec-tive was the proportion of patients clinically cured at 6 weeks follow-up. Secondary objec-tives were clinical cure at 12 weeks follow-up; parasitological cure at 6 and 12 weeks; adverse and drug related toxicity ev...
We report on 4 patients (1 immunocompetent, 3 immunosuppressed) in whom visceral leishmaniasis had b...
which permits unrestricted use, distribution, and reproduction in any medium, provided the original ...
A topical nanofiber nitric oxide (NO) releasing patch ( approximately 3.5 mumol NO/cm(2)/day for 20 ...
Standard treatment of cutaneous leishmaniasis (CL) in Suriname entails three injections of pentamidi...
BACKGROUND:American Cutaneous Leishmaniasis (ACL), a vector borne disease, is caused by various spec...
BackgroundAmerican Cutaneous Leishmaniasis (ACL), a vector borne disease, is caused by various speci...
International audienceBackground: New world cutaneous leishmaniasis (NWCL) can be found in French Gu...
Abstract: BACKGROUND: There have been few studies on pentamidine in the Americas; and there is no c...
Background: Cutaneous leishmaniasis is an annoying and disfiguring disease affecting around 1,500,00...
Purpose of review: Treatment of leishmaniasis is far from satisfactory: all antileishmanial drugs ar...
p.1-6Background: Cutaneous leishmaniasis (CL) is treated with parenteral drugs for decades with decr...
International audienceBACKGROUND: There is a need for a simple and efficacious treatment for cutaneo...
BACKGROUND: Cutaneous leishmaniasis (cl) is a disfiguring disease that confronts clinicians with a q...
BACKGROUND:Pentavalent antimonials (Sb5) are the first-line drugs for treating cutaneous leishmanias...
Background: Despite advances in diagnosis and treatment, leishmaniasis is now considered a severe pu...
We report on 4 patients (1 immunocompetent, 3 immunosuppressed) in whom visceral leishmaniasis had b...
which permits unrestricted use, distribution, and reproduction in any medium, provided the original ...
A topical nanofiber nitric oxide (NO) releasing patch ( approximately 3.5 mumol NO/cm(2)/day for 20 ...
Standard treatment of cutaneous leishmaniasis (CL) in Suriname entails three injections of pentamidi...
BACKGROUND:American Cutaneous Leishmaniasis (ACL), a vector borne disease, is caused by various spec...
BackgroundAmerican Cutaneous Leishmaniasis (ACL), a vector borne disease, is caused by various speci...
International audienceBackground: New world cutaneous leishmaniasis (NWCL) can be found in French Gu...
Abstract: BACKGROUND: There have been few studies on pentamidine in the Americas; and there is no c...
Background: Cutaneous leishmaniasis is an annoying and disfiguring disease affecting around 1,500,00...
Purpose of review: Treatment of leishmaniasis is far from satisfactory: all antileishmanial drugs ar...
p.1-6Background: Cutaneous leishmaniasis (CL) is treated with parenteral drugs for decades with decr...
International audienceBACKGROUND: There is a need for a simple and efficacious treatment for cutaneo...
BACKGROUND: Cutaneous leishmaniasis (cl) is a disfiguring disease that confronts clinicians with a q...
BACKGROUND:Pentavalent antimonials (Sb5) are the first-line drugs for treating cutaneous leishmanias...
Background: Despite advances in diagnosis and treatment, leishmaniasis is now considered a severe pu...
We report on 4 patients (1 immunocompetent, 3 immunosuppressed) in whom visceral leishmaniasis had b...
which permits unrestricted use, distribution, and reproduction in any medium, provided the original ...
A topical nanofiber nitric oxide (NO) releasing patch ( approximately 3.5 mumol NO/cm(2)/day for 20 ...